Eleven Biotherapeutics (EBIO) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Eleven Biotherapeutics (EBIO) Misses Q2 EPS by 8c
August 13, 2015 2:13 PM EDT
Leerink Partners analyst Jason Gerberry reiterated an Outperform rating and boosted his price target on Eleven Biotherapeutics (NASDAQ: EBIO) from $6 up to $8.35 following Q2 results and upside to EBI-005 phase 3 readout.
Gerberry noted that EBIO's Q2 loss of about $7 million was slightly narrower than the firm's outlook for a loss of about $8 million, which... More
August 12, 2015 5:26 PM EDT
Market wrap for August 12th
End of the Day: S&P 500 up 2.0 to 2,086.05; Dow Jones down 0.3 to 17,402.51; Nasdaq up 7.6 to 5,044.39
Market Brief: Stocks moved into positive territory late Wednesday as they looked to stave off broader pressure tied to China devaluing the yuan.
Macy's slumped amid mixed data points; the retailer's Q2 results laggest expectations, while it also announced expansion deals, which included a flagship store on Alibaba's Tmall.
Alibaba itself was hit after missing consensus Q2 estimates.
Ceres and... More
